Physicians

Department / Division
Medicine / Medicine - Oncology

Address
DUMC 3052
Durham, NC 27710

Appointment Telephone
919-668-6688

Office Telephone
919-681-6006

Fax Telephone
919-613-5228

Training

• MD, Jefferson Medical College of Thomas Jefferson University (Pennsylvania), 1988

Residency

• Internal Medicine, Michael Reese Hospital (Illinois), 1988-1991
• Oncology, Johns Hopkins Oncology Center (Maryland), 1992-1996

Clinical Interests
Phase 1 clinical trials involving new anti-cancer drugs, drug combinations, and combinations of new drugs with radiation; cancers of the GI system

Research Interests
Particular Clinical Interests and Skills: Phase I clinical trials involving new anti cancer drugs; drug combinations; and combinations of new drugs with radiation; cancers of the GI system

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Amgen, Inc.
• Bristol-Myers Squibb
• Centocor, Inc. (Johnson & Johnson)
• Cephalon, Inc.
• Genentech, Inc (Roche Holding)
• Hoffman LaRoche (Roche Holding)
• MethylGene Inc.
• Novartis
• Pfizer Inc.
• Sanofi-Aventis
• Threshold Pharmaceuticals
• Tracon

Representative Publications
Chakravarthy A, Abrams RA, Yeo CJ, Korman LT, Donehower RC, Hruban RH, Zahurek ML, Grochow LB, O'Reilly S, Hurwitz H, Jaffee EM, Lillemoe KD, Cameron JL. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1089-96. (2000)

Ochoa L, Hurwitz HI, Wilding G, Cohen D, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. Ann Oncol. 2000 Oct;11(10):1313-22. (2000)

White R, Lee C, Anscher M, Gottfried M, Wolff R, Keogan M, Pappas T, Hurwitz H, Tyler D. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol. 1999 Jan-Feb;6(1):38-45. (1999)

Abrams RA. Cardinale RM. Enger C. Haulk TL. Hurwitz H. Osterman F. Sitzmann JV. Influence of prognostic groupings and treatment results in the management of unresectable hepatoma: experience with Cisplatinum-based chemoradiotherapy in 76 patients. [Journal Article] International Journal of Radiation Oncology, Biology, Physics. 39(5):1077-85, 1997 Dec (1997)

Katz A. Vlodavsky I. Davies M. Miao HQ. Ben-Sasson SA. Darmon D. Hurwitz H. Borgel H. Benezra M. Antiproliferative activity to glomerular mesangial cells and receptor binding of a heparin-mimicking polyaromatic anionic compound. [Journal Article] Journal of the American Society of Nephrology. 8(11):1688-97, 1997 Nov. (1997)